Learner Objectives
Upon completion of this activity, you should be able to:
- Describe the role of hs-CRP as a biomarker in measuring inflammation and CVD risk.
- Explain the significance of hs-CRP screening and testing in cardiovascular health.
Faculty
Antonio Abbate, MD, FACC
Professor of Cardiology
UVA Health
Disclosures
Consultant Fees/Honoraria: Cardiol Rx, Kiniksa, MonterosaTX, Novo Nordisk Inc.
Michael Seth Garshick, MD
Cardiologist and Assistant Professor
New York University (NYU) Langone Health
Disclosures
Consultant Fees/Honoraria: Abbvie, BMS, Horizon Therapeutics, Kiniksa
Planning Committee
Director, Cardio-Rheumatology Clinic
Division of Preventive Cardiology, Division of Cardiovascular Imaging, Brigham and Women's Hospital
Disclosures
Consultant Fees/Honoraria: Kiniksa Pharmaceuticals, Novo Nordisk Inc., Oruka
Target Audience
The target audience for this education is Cardiologists, Cardiovascular nurses, Nurse practitioners specializing in cardiology, Physician assistants working in cardiology.
Important Dates
Date of Release: November 4, 2026
Term of Approval/Date of Expiration: November 4, 2027
Grant Acknowledgement
Educational grant support for this activity provided by: Novo Nordisk